Roche said its VENTANA PTEN (SP218) RxDx Assay is the first IHC companion diagnostic approved by the FDA for determining PTEN protein loss. The approval supports Roche's diagnostics portfolio and could strengthen its position in oncology testing, though the article provides no commercial size or financial impact. The news is positive for Roche and broadly relevant to regulated biotech diagnostics.
Roche said its VENTANA PTEN (SP218) RxDx Assay is the first IHC companion diagnostic approved by the FDA for determining PTEN protein loss. The approval supports Roche's diagnostics portfolio and could strengthen its position in oncology testing, though the article provides no commercial size or financial impact. The news is positive for Roche and broadly relevant to regulated biotech diagnostics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
